JYNT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

14.12M

-55.83%

0.045

-125%

14.11M

+7.88%

0.150

+200%

14.58M

+9.89%

0.190

+1800%

Estimates Revision

The market is revising Downward the revenue expectations for The Joint Corp. (JYNT) for FY2025, with the revenue forecasts being adjusted by -0.86% over the past three months. During the same period, the stock price has changed by 14.64%.

Revenue Estimates for FY2025

Revise Downward

-0.86%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-15.62%

In Past 3 Month

Stock Price

Go Up

+14.64%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast JYNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JYNT is 11.33 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

11.33

High

14.00

Current: 0.000

Low

9.00

Averages

11.33

High

14.00

B. Riley

Buy -> Neutral

downgrade

$18 -> $9

2025-11-07

Reason

B. Riley

Price Target

$18 -> $9

2025-11-07

downgrade

Buy -> Neutral

Reason

B. Riley downgraded Joint Corp. to Neutral from Buy with a price target of $9, down from $18. The company's Q3 comps were down 2.0%, reflecting continued softness in new patient acquisition, the analyst tells investors in a research note. The firm Joint's fiscal 2025 as "transitional," as the company tests initiatives and completes refranchising. It cites deteriorating trends for the downgrade.

Lake Street

Ryan Meyers

Buy

downgrade

$16 -> $11

2025-11-07

Reason

Lake Street

Ryan Meyers

Price Target

$16 -> $11

2025-11-07

downgrade

Buy

Reason

Lake Street analyst Ryan Meyers lowered the firm's price target on Joint Corp. to $11 from $16 and keeps a Buy rating on the shares. The transition toward a fully franchised model has taken longer than originally expected, says the analyst, who lowers the firm's price target as the underlying fundamentals at the clinic level remain soft.

Roth Capital

Buy

maintain

$15 -> $14

2025-11-07

Reason

Roth Capital

Price Target

$15 -> $14

2025-11-07

maintain

Buy

Reason

Roth Capital lowered the firm's price target on Joint Corp. to $14 from $15 and keeps a Buy rating on the shares after its Q3 results. Refranchising process continues to progress, albeit slowly, but the firm remains confident that margin and free cash flow will inflect higher upon completion, the analyst tells investors in a research note.

Lake Street

Ryan Meyers

Buy

downgrade

$20 -> $16

2025-05-09

Reason

Lake Street

Ryan Meyers

Price Target

$20 -> $16

2025-05-09

downgrade

Buy

Reason

Lake Street analyst Ryan Meyers lowered the firm's price target on Joint Corp. to $16 from $20 and keeps a Buy rating on the shares. The firm believes The Joint continues to make positive strides in its corporate clinic transition following its first quarter 2025 results, but is trimming its price target based on a lower 2026 EBITDA estimate.

Valuation Metrics

The current forward P/E ratio for Joint Corp (JYNT.O) is 15.66, compared to its 5-year average forward P/E of 112.29. For a more detailed relative valuation and DCF analysis to assess Joint Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

112.29

Current PE

15.66

Overvalued PE

210.82

Undervalued PE

13.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

28.06

Current EV/EBITDA

8.99

Overvalued EV/EBITDA

51.84

Undervalued EV/EBITDA

4.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.01

Current PS

2.29

Overvalued PS

7.96

Undervalued PS

0.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

JYNT News & Events

Events Timeline

No data

News

5.0

01-05Globenewswire

The Joint Corp. Appoints Ron Stilwell as Senior VP of Operations and Patient Experience

5.0

01-05Newsfilter

The Joint Corp. Appoints Ron Stilwell as SVP of Operations and Patient Experience

4.5

2025-12-18NASDAQ.COM

Thursday's Underperforming Sectors: Oil & Gas Exploration, Rental, Leasing, and Royalty Stocks

People Also Watch

Frequently Asked Questions

What is Joint Corp (JYNT) stock price today?

The current price of JYNT is 9.24 USD — it has increased 2.9 % in the last trading day.

What is Joint Corp (JYNT)'s business?

The Joint Corp. is a franchisor and operator of chiropractic clinics that uses a private pay, non-insurance, cash-based model. The Company operates the Franchise Operations segment. The Company and its franchisees provide management services to affiliate professional chiropractic practices. The franchise system consists of approximately 811 clinics in operation. It offers a range of membership and wellness packages. It offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. Each patient's records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.

What is the price predicton of JYNT Stock?

What is Joint Corp (JYNT)'s revenue for the last quarter?

Joint Corp revenue for the last quarter amounts to 13.38M USD, increased 5.74 % YoY.

What is Joint Corp (JYNT)'s earnings per share (EPS) for the last quarter?

Joint Corp. EPS for the last quarter amounts to 0.06 USD, decreased -128.57 % YoY.

What changes have occurred in the market's expectations for Joint Corp (JYNT)'s fundamentals?

How many employees does Joint Corp (JYNT). have?

Joint Corp (JYNT) has 443 emplpoyees as of January 10 2026.

What is Joint Corp (JYNT) market cap?

Today JYNT has the market capitalization of 137.36M USD.